{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:29:54Z","timestamp":1780428594291,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016309","name":"Bayer plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016309","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.euros.2025.07.003","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T11:58:53Z","timestamp":1753531133000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials"],"prefix":"10.1016","volume":"79","author":[{"given":"Bhavna","family":"Oza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-292X","authenticated-orcid":false,"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant D.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.07.003_b0005","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/curroncol30010070","article-title":"Navigating the current landscape of non-clear cell renal cell carcinoma: a review of the literature","volume":"30","author":"John","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.euros.2025.07.003_b0010","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.07.003_b0015","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: biology, natural history and management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euros.2025.07.003_b0020","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2019 update","volume":"75","author":"Ljungberg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.07.003_b0025","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2025.07.003_b0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euros.2025.07.003_b0035","unstructured":"The British Association of Urological Surgeons. Urology: Towards better care for patients with kidney cancer. 2023. https:\/\/gettingitrightfirsttime.co.uk\/girft-guide-supports-better-care-for-people-with-kidney-cancer\/."},{"key":"10.1016\/j.euros.2025.07.003_b0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.euros.2023.05.005","article-title":"Assessment of the VENUSS and GRANT models for individual prediction of cancer-specific survival in surgically treated nonmetastatic papillary renal cell carcinoma","volume":"53","author":"Piccinelli","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euros.2025.07.003_b0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12916-019-1419-1","article-title":"The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort","volume":"17","author":"Klatte","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.euros.2025.07.003_b0050","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.2001.19.6.1649","article-title":"Improved prognostication of renal cell carcinoma using an integrated staging system","volume":"19","author":"Zisman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.07.003_b0055","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3390\/cancers15072155","article-title":"Critical appraisal of Leibovich 2018 and GRANT models for prediction of cancer-specific survival in non-metastatic chromophobe renal cell carcinoma","volume":"15","author":"Piccinelli","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euros.2025.07.003_b0060","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.euo.2020.09.005","article-title":"The impact of histological subtype on the incidence, timing, and patterns of recurrence in patients with renal cell carcinoma after surgery\u2014results from RECUR consortium","volume":"4","author":"Abu-Ghanem","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2025.07.003_b0065","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.07.003_b0070","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1200\/JCO.20.01800","article-title":"Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial","volume":"38","author":"Eisen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.07.003_b0075","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jamaoncol.2017.0076","article-title":"Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial","volume":"3","author":"Haas","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euros.2025.07.003_b0080","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"97","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2025.07.003_b0085","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.21.01090","article-title":"External validation of the 2003 Leibovich prognostic score in patients randomly assigned to SORCE, an international phase III trial of adjuvant sorafenib in renal cell cancer","volume":"40","author":"Oza","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.07.003_b0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euros.2025.07.003_b0095","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1007\/s00345-021-03683-9","article-title":"Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma","volume":"39","author":"Neves","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2025.07.003_b0100","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.juro.2016.03.144","article-title":"The role of metastasectomy in patients with renal cell carcinoma with sarcomatoid dedifferentiation: a matched controlled analysis","volume":"196","author":"Thomas","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.07.003_b0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.2011-0227","article-title":"Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies","volume":"17","author":"Shuch","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.euros.2025.07.003_b0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15586\/jkcvhl.v10i4.294","article-title":"Papillary renal cell carcinoma: demographics, survival analysis, racial disparities, and genomic landscape","volume":"10","author":"Ullah","year":"2023","journal-title":"J Kidney Cancer VHL"},{"key":"10.1016\/j.euros.2025.07.003_b0115","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016309","article-title":"A comparison of the prognosis of papillary and clear cell renal cell carcinoma: evidence from a meta-analysis","volume":"98","author":"Deng","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.euros.2025.07.003_b0120","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.urolonc.2016.01.005","article-title":"Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy","volume":"34","author":"Nguyen","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2025.07.003_b0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.juro.2018.08.041","article-title":"Patterns of relapse and implications for post-nephrectomy surveillance in patients with high risk nonclear cell renal cell carcinoma: subgroup analysis of the phase 3 ECOG-ACRIN E2805 trial","volume":"201","author":"Narayan","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.07.003_b0130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.urolonc.2020.01.013","article-title":"Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma","volume":"38","author":"Rosiello","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2025.07.003_b0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2017.07.042","article-title":"Retroperitoneal lymphadenectomy for high risk, nonmetastatic renal cell carcinoma: an analysis of the ASSURE (ECOG-ACRIN 2805) adjuvant trial","volume":"199","author":"Ristau","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.07.003_b0140","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.urology.2017.02.012","article-title":"Long-term survival after resection of sentinel node metastatic renal cell carcinoma","volume":"103","author":"Kuusk","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.euros.2025.07.003_b0145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euros.2025.07.003_b0150","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1470-2045(15)70167-1","article-title":"A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies","volume":"16","author":"Rini","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325002484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325002484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:38:12Z","timestamp":1758710292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325002484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"alternative-id":["S2666168325002484"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.07.003","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}